CBR-5884 (681159-27-3) is a potent and selective inhibitor of 3-phosphoglycerate dehydrogenase (PHGDH), IC50=33 μM.1?The action of PHGDH is the first committed step of serine biosynthesis2?and certain cancer cells overexpress PHGDH3. CBR-5884 inhibits serine biosynthesis in cells with no effect on two other dehydrogenases, lactate dehydrogenase and MDH1 and without general cytotoxic effects up to 40 μM. CBR-5884 is selectively toxic to tumor cells with high serine synthesis activity. A novel tool for selective inhibition of serine biosynthesis in cells which also provides further proof that PHGDH is a viable target for the development of novel anticancer agents.1
CBR-5884 has been used as a 3-phosphoglycerate dehydrogenase (PHGDH) inhibitor to explore the role of PHGDH in Müller cells from different retinal regions and also used in trypan blue exclusion assay to determine the number of viable MYCN cells.
CBR-5884 is a cell penetrant, potent and selective noncompetitive inhibitor of 3-phosphoglycerate dehydrogenase (PHGDH) that inhibits proliferation of melanoma and breast cancer lines. CBR-5884 inhibits de novo serine synthesis in in cancer cells.
1) Mullarky?et al. (2016),?Identification of a small molecule inhibitor of 3-phosphoglycerate dehydrogenase to target serine biosynthesis in cancers; Proc. Natl. Acad. Sci. USA,?113?1778
2) Snell et al.?(1986),?The duality of pathways for serine biosynthesis is a fallacy; Trends Biochem. Sci.,?11(6)?241
3) DeNicola?et al. (2015),?NFR2 regulates serine biosynthesis in non-small cell lung cancer; Nat. Genet.,?47?1475
